Skip to main content

Evotec SE (EVO)

NASDAQ: EVO · IEX Real-Time Price · USD
22.50 -0.60 (-2.60%)
Dec 3, 2021 4:00 PM EST - Market closed
Market Cap7.90B
Revenue (ttm)661.93M
Net Income (ttm)136.62M
Shares Out351.22M
EPS (ttm)0.39
PE Ratio57.84
Forward PE89.29
Dividendn/a
Ex-Dividend Daten/a
Volume43,779
Open23.26
Previous Close23.10
Day's Range22.29 - 23.35
52-Week Range20.90 - 24.36
Beta0.85
Analystsn/a
Price Targetn/a
Earnings DateNov 18, 2021

About EVO

Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. In order to address demand for faster, cheaper and better outcomes of early-stage drug discovery processes, we deliver fully-integrated drug discovery and development programs to our partners. Our expertise in deep learning and computational approaches and the integration of such knowledge across the full value chain of research, drug discovery and development is industry-leading. We possess capabilities across the early stage...

IndustryDrug Manufacturers-Specialty & Generic
IPO DateNov 4, 2021
CEOWerner Lanthaler
Employees4,081
Stock ExchangeNASDAQ
Ticker SymbolEVO
Full Company Profile

Financial Performance

In 2020, Evotec SE's revenue was 500.92 million, an increase of 12.20% compared to the previous year's 446.44 million. Earnings were 6.25 million, a decrease of -83.58%.

Financial numbers in millions EURFinancial Statements

News

EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

CAMBRIDGE, Mass. & HAMBURG, Germany--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and...

2 weeks ago - Business Wire

Evotec and EQRx Announce Integrated Drug Discovery and Development Partnership

EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND ACCE...

2 weeks ago - Accesswire

Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update

STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH CO-OWNED PIPELINE GAINING MOMENTUM J.POD (R) REDMOND (US) OPERATIONAL SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END) GUIDANCE ...

3 weeks ago - Accesswire

Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb

THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / November 10, 2021 / Evotec SE (Frankfurt Stock Exchange...

3 weeks ago - Accesswire

Evotec SE Announces Closing of Public Offering

HAMBURG, GERMANY / ACCESSWIRE / November 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today the closing of its public offering on 08 Novembe...

3 weeks ago - Accesswire

Germany-listed drug discovery company Evotec files for a $100 million US IPO

Evotec, which provides drug discovery solutions for the pharmaceutical industry, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - Renaissance Capital

Evotec IPO Registration Document (F-1)

Evotec SE has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its collaboration with Bristol Myers Squibb (NYSE: BMY) has been expanded to include a new cell type, trig...

1 month ago - ACCESSWIRE